Glipament MV 1 Tablet ER is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.3 mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing postprandial and fasting blood glucose levels. Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, facilitating increased glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, mitigating postprandial hyperglycemia. The extended-release formulation ensures sustained drug release, promoting better patient compliance and stable plasma concentrations. Glipament MV 1 is indicated as an adjunct to diet and exercise in patients inadequately controlled on monotherapy or dual therapy with these agents. It is essential to monitor renal function and glycemic parameters regularly during therapy to minimize adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis risk. Dose adjustments may be necessary based on clinical response and tolerability. This combination offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects.